Factors Associated With Cost Barriers to Asthma Management by Insurance Coverage Status Among US Adults

IF 7.2 1区 医学 Q1 ALLERGY Journal of Allergy and Clinical Immunology-In Practice Pub Date : 2025-06-01 Epub Date: 2025-03-25 DOI:10.1016/j.jaip.2025.03.021
Luyu Xie PharmD, PhD , Yixin Tang EdM , Rebecca I. Felix-George PharmD, MPH , Joseph H. Joo MD , Yutong Chen PhD , Yadira Rivera-Sanchez MD , Joshua M. Liao MD, MSc
{"title":"Factors Associated With Cost Barriers to Asthma Management by Insurance Coverage Status Among US Adults","authors":"Luyu Xie PharmD, PhD ,&nbsp;Yixin Tang EdM ,&nbsp;Rebecca I. Felix-George PharmD, MPH ,&nbsp;Joseph H. Joo MD ,&nbsp;Yutong Chen PhD ,&nbsp;Yadira Rivera-Sanchez MD ,&nbsp;Joshua M. Liao MD, MSc","doi":"10.1016/j.jaip.2025.03.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Asthma is a common chronic condition in the United States, yet despite insurance coverage, patients with asthma can potentially face cost barriers and limit access to care.</div></div><div><h3>Objective</h3><div>To investigate the predictors of cost barriers in asthma care and explore variations based on insurance coverage status.</div></div><div><h3>Methods</h3><div>We used 2019 to 2021 Behavioral Risk Factor Surveillance System Survey data and multivariable logistic regression to evaluate the relationship between insurance coverage (full year vs partial or no coverage) as study exposure and self-reported cost barriers (to primary care, asthma specialists, and asthma medications) as study outcomes.</div></div><div><h3>Results</h3><div>Among 25,996 patients, 86.3% had full-year insurance coverage whereas 13.7% had partial or no insurance coverage. Almost half of patients with partial or no coverage reported cost barriers (28.4% to primary care, 13.9% to asthma specialists, and 33% to asthma medications) compared with 10.6% fully insured individuals (3.3% to primary care, 2.7% to asthma specialists, and 8.3% to asthma medications; <em>P</em> &lt; .001). Non-Hispanic Black people with full-year insurance were more likely to face primary care cost barriers than were non-Hispanic White people (odds ratio = 1.91; 95% CI, 1.19-3.07). Males were less likely to have asthma medication cost barriers than were females regardless of insurance status. In addition, among fully insured participants, older age, higher income, and longer time since last asthma symptoms reduced any cost barriers, whereas recent emergency department visits or hospitalizations increased them (odds ratio = 2.23; 95% CI, 1.74-2.86). In partially or uninsured participants, higher income and time since symptoms were protective, but emergency department visits or hospitalizations also increased cost barriers.</div></div><div><h3>Conclusions</h3><div>Although partially or uninsured individuals face greater cost challenges, fully insured individuals also experience significant barriers, particularly among specific subgroups such as non-Hispanic Black people. Targeted interventions are crucial to addressing these disparities and improving access to affordable asthma care for all.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 6","pages":"Pages 1412-1420.e1"},"PeriodicalIF":7.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213219825002715","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Asthma is a common chronic condition in the United States, yet despite insurance coverage, patients with asthma can potentially face cost barriers and limit access to care.

Objective

To investigate the predictors of cost barriers in asthma care and explore variations based on insurance coverage status.

Methods

We used 2019 to 2021 Behavioral Risk Factor Surveillance System Survey data and multivariable logistic regression to evaluate the relationship between insurance coverage (full year vs partial or no coverage) as study exposure and self-reported cost barriers (to primary care, asthma specialists, and asthma medications) as study outcomes.

Results

Among 25,996 patients, 86.3% had full-year insurance coverage whereas 13.7% had partial or no insurance coverage. Almost half of patients with partial or no coverage reported cost barriers (28.4% to primary care, 13.9% to asthma specialists, and 33% to asthma medications) compared with 10.6% fully insured individuals (3.3% to primary care, 2.7% to asthma specialists, and 8.3% to asthma medications; P < .001). Non-Hispanic Black people with full-year insurance were more likely to face primary care cost barriers than were non-Hispanic White people (odds ratio = 1.91; 95% CI, 1.19-3.07). Males were less likely to have asthma medication cost barriers than were females regardless of insurance status. In addition, among fully insured participants, older age, higher income, and longer time since last asthma symptoms reduced any cost barriers, whereas recent emergency department visits or hospitalizations increased them (odds ratio = 2.23; 95% CI, 1.74-2.86). In partially or uninsured participants, higher income and time since symptoms were protective, but emergency department visits or hospitalizations also increased cost barriers.

Conclusions

Although partially or uninsured individuals face greater cost challenges, fully insured individuals also experience significant barriers, particularly among specific subgroups such as non-Hispanic Black people. Targeted interventions are crucial to addressing these disparities and improving access to affordable asthma care for all.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国成年人哮喘治疗费用障碍的相关因素(按保险覆盖状况分类)。
背景:哮喘在美国是一种常见的慢性疾病,然而尽管有保险覆盖,哮喘患者仍然可能面临成本障碍,并限制获得护理。目的:探讨哮喘护理成本障碍的预测因素,并探讨不同保险覆盖状况下的差异。方法:我们使用2019-2021年行为风险因素监测系统调查数据和多变量logistic回归来评估保险覆盖率(全年vs部分/无保险)作为研究暴露和自我报告的成本障碍(初级保健、哮喘专家、哮喘药物)作为研究结果之间的关系。结果:25996例患者中,86.3%的患者有全年保险,13.7%的患者有部分保险或无保险。几乎一半的部分保险/无保险患者报告了成本障碍(28.4%的人选择初级保健,13.9%的人选择哮喘专科医生,33%的人选择哮喘药物),而完全保险个体的这一比例为10.6%(3.3%的人选择初级保健,2.7%的人选择哮喘专科医生,8.3%的人选择哮喘药物)(P < 0.001)。拥有全年保险的非西班牙裔黑人比非西班牙裔白人更有可能面临初级保健费用障碍(OR: 1.91, 95% CI: 1.19-3.07)。无论保险状况如何,男性比女性更不可能有哮喘药物费用障碍。此外,在完全参保的参与者中,年龄较大、收入较高、上一次哮喘症状后时间较长降低了任何费用障碍,而最近的急诊或住院则增加了这些障碍(or: 2.23, 95% CI: 1.74-2.86)。在部分/未投保的参与者中,较高的收入和出现症状后的时间具有保护作用,但急诊科就诊或住院也增加了成本障碍。结论:虽然部分或未投保的个人面临更大的成本挑战,但完全投保的个人也经历了重大障碍,特别是在特定的亚群体中,如非西班牙裔黑人。有针对性的干预措施对于解决这些差异和改善所有人获得负担得起的哮喘护理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.10
自引率
9.60%
发文量
683
审稿时长
50 days
期刊介绍: JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases. This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.
期刊最新文献
Timing of High-Risk Asthma Specialist Enrollment and Severe Asthma Exacerbations in Children. Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level. Acalabrutinib for long-term prevention of recurrent idiopathic anaphylaxis. Comparative Efficacy of Subcutaneous and Sublingual Allergen Immunotherapy for Grass Pollen-Induced Allergic Rhinoconjunctivitis: Pairwise and Adjusted Indirect Treatment Comparison of Standardized ALK Products. Allergic rhinitis in the elderly. In collaboration with ARIA guidelines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1